Neoantigen Vaccines Pass the Immunogenicity Test

Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self antigens and represent a new class of targets for cancer immunotherapy. Recent reports on various vaccine platforms targeting neoantigens suggest a basis for precision therapies customized to each patient’s tum...

Full description

Saved in:
Bibliographic Details
Published inTrends in molecular medicine Vol. 23; no. 10; pp. 869 - 871
Main Authors Linette, Gerald P., Carreno, Beatriz M.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2017
Subjects
Animals
Antigens, Neoplasm - immunology
Antigens, Neoplasm - therapeutic use
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
Humans
Immunogenicity, Vaccine
Immunotherapy
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Online AccessGet full text

Cover

More Information
Summary:Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self antigens and represent a new class of targets for cancer immunotherapy. Recent reports on various vaccine platforms targeting neoantigens suggest a basis for precision therapies customized to each patient’s tumor mutational profile.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1471-4914
1471-499X
DOI:10.1016/j.molmed.2017.08.007